Poland· PL-100420992
Dovato
A lamivudine and dolutegravir product containing dolutegravirum + lamivudinum, registered in Poland by ViiV Healthcare BV. The same ATC class is registered in 13 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Lamivudine and dolutegravir is registered in 13 of 19 countries.
Countries holding a registration under ATC J05AR25 (lamivudine and dolutegravir), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 8 of them publish a price we can compare per daily dose
Lamivudine and dolutegravir · ATC J05AR25
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Dolutegravirum + Lamivudinum
- Manufacturer
- ViiV Healthcare BV
- Country
- Poland (PL)
- ATC code
- J05AR25
- ATC class
- Lamivudine and dolutegravir
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 4
- gtin05909991404345
- gtin05909991404352
- gtin05909991521592
- gtin05909991521608
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Lamivudine and dolutegravir in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaDOVATOViiV Healthcare BV, Amersfoort
- United StatesDovatoViiV Healthcare Company
- FinlandDovatoViiV Healthcare BV
- SwitzerlandDovato
- SpainDOVATO 50 MG/300 MG COMPRIMIDOS RECUBIERTOS CON PELICULAViiv Healthcare B.V.
- IcelandDOVATOViiV Healthcare BV
- NetherlandsDovato 50 mg/300 mg filmomhulde tablettenViiV healthcare B.V.
- NorwayDovatoViiV Healthcare BV (1)
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Dovato
- Liechtenstein · Dovato
- Norway · Dovato
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/7ab1e338-9446-497f-87d9-229face2758e GET /v1/drugs/7ab1e338-9446-497f-87d9-229face2758e?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki powlekane",
"source": "urpl",
"strength": "50 mg + 300 mg",
"packaging": "05909991404345 ¦ Rpz ¦ EU/1/19/1370/001 ¦ 132739\n1 butelka 30 tabl.\n05909991404352 ¦ Rpz ¦ EU/1/19/1370/002 ¦ 132740\n3 butelki 30 tabl.\n05909991521592 ¦ Rpz ¦ EU/1/19/1370/004 ¦ 151286\n90 tabl.\n05909991521608 ¦ Rpz ¦ EU/1/19/1370/003 ¦ 151287\n30 tabl.",
"substance": "Dolutegravirum 50 mg + Lamivudinum 300 mg",
"common_name": "Dolutegravirum + Lamivudinum",
"pl_product_id": "100420992",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about lamivudine and dolutegravir.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.